Recent studies have demonstrated the feasibility and therapeutic efficacy of engineered TCR T cell approaches in malignant tumours.84 Furthermore, transgenic TCR T cell therapies are being investigated as an MM treatment, with current research focussing on targeting cancer testis antigens such as NY-ESO1, the B cell-specific transcription factor BOB1, or the intracellular transcription factor Wilms tumour-1 (WT1). This evidence concerns the gene PPIB and cancer.